EPHA2 and neoplasm: Therefore, rather than broad MEK‐ERK1/2 pathway inhibition or EphA2 knockdown, the specific RSK‐EphA2‐pS897 blockade and consequent reversal to tumor‐suppressive EphA2‐pY588 correlated with the effective OC cell elimination and sensitization to platinum.